This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read AbbVie’s 8K filing here.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Recommended Stories
- Five stocks we like better than AbbVie
- Why is the Ex-Dividend Date Significant to Investors?
- Forget Tesla: 3 Stocks to Ride the Elon Musk Effect
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- David Tepper Loads Up on China—These 5 Stocks Stand Out
- How is Compound Interest Calculated?
- Datadog Is in the Doghouse, But This Dip Spells Opportunity
